drug
lubiprostone
Marketedupdated 3mo agoby Mallinckrodt LLC
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying lubiprostone
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 23, 2027
161 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- Oct 25, 2027formulationUS 80263931.2y
- Oct 25, 2027formulationUS 80263931.2y
- Jan 23, 2027formulationUS 8338639161d
- Jan 23, 2027formulationUS 8338639161d
- Jan 23, 2027formulationUS 8779187161d
- Jan 23, 2027formulationUS 8779187161d
News(1)
- Takeda says it expects to take $2.5B hit after Amitiza antitrust verdict, with plans to appealTakeda has updated its financial results to reflect costs it could incur after losing an antitrust lawsuit concerning its laxative drug Amitiza. In May, the US District Court in Massachusetts ruled…endpoints · 2mo ago
Data sources
last refreshed 38m ago
Found something off?
comments(0)
5-min edit window · permanent after that